257 related articles for article (PubMed ID: 37532934)
21. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
[TBL] [Abstract][Full Text] [Related]
22. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.
Randall ME; Filiaci V; McMeekin DS; von Gruenigen V; Huang H; Yashar CM; Mannel RS; Kim JW; Salani R; DiSilvestro PA; Burke JJ; Rutherford T; Spirtos NM; Terada K; Anderson PR; Brewster WR; Small W; Aghajanian CA; Miller DS
J Clin Oncol; 2019 Jul; 37(21):1810-1818. PubMed ID: 30995174
[TBL] [Abstract][Full Text] [Related]
23. Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses.
Suvilesh KN; Nussbaum YI; Radhakrishnan V; Manjunath Y; Avella DM; Staveley-O'Carroll KF; Kimchi ET; Chaudhuri AA; Shyu CR; Li G; Pantel K; Warren WC; Mitchem JB; Kaifi JT
Mol Cancer; 2022 Mar; 21(1):73. PubMed ID: 35279152
[TBL] [Abstract][Full Text] [Related]
24. The Role of ROR1 in Chemoresistance and EMT in Endometrial Cancer Cells.
Lee KJ; Kim NH; Kim HS; Kim Y; Lee JJ; Kim JH; Cho HY; Jeong SY; Park ST
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241228
[No Abstract] [Full Text] [Related]
25. Integrated single-cell RNA sequencing and spatial transcriptomics analysis reveals the tumour microenvironment in patients with endometrial cancer responding to anti-PD-1 treatment.
Chen J; Song Y; Huang J; Wan X; Li Y
Clin Transl Med; 2024 Apr; 14(4):e1668. PubMed ID: 38649737
[No Abstract] [Full Text] [Related]
26. Netrin-1 expression and targeting in multiple myeloma.
Fahed D; Chettab A; Mathe D; Denis M; Traverse-Glehen A; Karlin L; Perrial E; Dumontet C
Leuk Lymphoma; 2022 Feb; 63(2):395-403. PubMed ID: 34585999
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer.
Xiao Y; Jin L; Deng C; Guan Y; Kalogera E; Ray U; Thirusangu P; Staub J; Sarkar Bhattacharya S; Xu H; Fang X; Shridhar V
Oncogene; 2021 Feb; 40(8):1409-1424. PubMed ID: 33420377
[TBL] [Abstract][Full Text] [Related]
28. Establishing a Prognostic Signature Based on Epithelial-Mesenchymal Transition-Related Genes for Endometrial Cancer Patients.
Liu J; Cui G; Shen S; Gao F; Zhu H; Xu Y
Front Immunol; 2021; 12():805883. PubMed ID: 35095892
[TBL] [Abstract][Full Text] [Related]
29. The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.
Brozovic A; Duran GE; Wang YC; Francisco EB; Sikic BI
Mol Oncol; 2015 Oct; 9(8):1678-93. PubMed ID: 26025631
[TBL] [Abstract][Full Text] [Related]
30. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
Kharma B; Baba T; Mandai M; Matsumura N; Murphy SK; Kang HS; Yamanoi K; Hamanishi J; Yamaguchi K; Yoshioka Y; Konishi I
Int J Cancer; 2013 Nov; 133(9):2234-44. PubMed ID: 23595697
[TBL] [Abstract][Full Text] [Related]
31. Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer.
Fujiwara A; Shintani Y; Funaki S; Kawamura T; Kimura T; Minami M; Okumura M
Lung Cancer; 2017 Apr; 106():8-16. PubMed ID: 28285699
[TBL] [Abstract][Full Text] [Related]
32. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR; Chase DM; Slomovitz BM; dePont Christensen R; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Gold MA; Auranen A; Pothuri B; Cibula D; McCourt C; Raspagliesi F; Shahin MS; Gill SE; Monk BJ; Buscema J; Herzog TJ; Copeland LJ; Tian M; He Z; Stevens S; Zografos E; Coleman RL; Powell MA;
N Engl J Med; 2023 Jun; 388(23):2145-2158. PubMed ID: 36972026
[TBL] [Abstract][Full Text] [Related]
33. Netrin-1 elicits metastatic potential of non-small cell lung carcinoma cell by enhancing cell invasion, migration and vasculogenic mimicry via EMT induction.
Zhang X; Cui P; Ding B; Guo Y; Han K; Li J; Chen H; Zhang W
Cancer Gene Ther; 2018 Feb; 25(1-2):18-26. PubMed ID: 29234153
[TBL] [Abstract][Full Text] [Related]
34. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial.
Zhong H; Sun S; Chen J; Wang Z; Zhao Y; Zhang G; Chen G; Zhou M; Zhou J; Du Y; Wu L; Xu Z; Mei X; Zhang W; He J; Cui J; Zhang Z; Luo H; Liu W; Sun M; Wu J; Shen Y; Zhang S; Yang N; Wang M; Lu J; Li K; Yao W; Sun Q; Yue H; Wang L; Ye S; Li B; Zhuang X; Pan Y; Zhang M; Shu Y; He Z; Pan L; Ling Y; Liu S; Zhang Q; Jiao S; Han B
Lancet Respir Med; 2024 May; 12(5):355-365. PubMed ID: 38309287
[TBL] [Abstract][Full Text] [Related]
35. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
36. MiR-195 inhibits migration, invasion and epithelial-mesenchymal transition (EMT) of endometrial carcinoma cells by targeting SOX4.
Zhao X; Dai L; Yue Q; Wang H; Wang XU; Li Y; Chen R
J Biosci; 2019 Dec; 44(6):. PubMed ID: 31894127
[TBL] [Abstract][Full Text] [Related]
37. High-throughput mRNA and miRNA profiling of epithelial-mesenchymal transition in MDCK cells.
Shukla P; Vogl C; Wallner B; Rigler D; Müller M; Macho-Maschler S
BMC Genomics; 2015 Nov; 16():944. PubMed ID: 26572553
[TBL] [Abstract][Full Text] [Related]
38. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
Byron SA; Loch DC; Pollock PM
Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study.
Coleman RL; Hu W; Soliman P; Nick A; Ramirez PT; Westin SN; Garcia ME; Zhu Z; Palancia J; Fellman BM; Yuan Y; Ram P; Bischoff F; Schmeler K; Bodurka D; Meyer LA; Sood AK
Gynecol Oncol; 2021 Apr; 161(1):104-112. PubMed ID: 33551196
[TBL] [Abstract][Full Text] [Related]
40. COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer.
Zhou Z; Jin L; Shen J; Shi W; Xu Y; Ye L; Liu J; Pan J
Acta Biochim Biophys Sin (Shanghai); 2022 Dec; 55(1):34-42. PubMed ID: 36647720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
